SEARCH:   Advanced

Blood, 1 June 2006, Vol. 107, No. 11, pp. 4207-4213. Prepublished online as a Blood First Edition Paper on January 31, 2006; DOI 10.1182/blood-2005-10-4222. This Article Full Text Full Text (PDF) Erratum (v109,p2292) All Versions of this Article: 2005-10-4222v1 107/11/4207    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Winter, J. N. Articles by Gascoyne, R. D. Search for Related Content PubMed PubMed Citation Articles by Winter, J. N. Articles by Gascoyne, R. D. Related Collections Neoplasia Free Research Articles Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  PLENARY PAPERS Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study Jane N. Winter, Edie A. Weller, Sandra J. Horning, Maryla Krajewska, Daina Variakojis, Thomas M. Habermann, Richard I. Fisher, Paul J. Kurtin, William R. Macon, Mukesh Chhanabhai, Raymond E. Felgar, Eric D. Hsi, L. Jeffrey Medeiros, James K. Weick, John C. Reed, and Randy D. Gascoyne From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL; Dana Farber Cancer Institute, Boston, MA; Stanford University, CA; Burnham Institute for Medical Research, La Jolla, CA; Mayo Clinic College of Medicine, Rochester, MN; James P. Wilmot Cancer Center, University of Rochester Medical Center, NY; British Columbia Cancer Agency, Vancouver, BC, Canada; Cleveland Clinic, OH; M. D. Anderson Cancer Center, Houston, TX; and Hematology Oncology Associates of the Palm Beaches, Lake Worth, FL. Bcl-6 protein expression, a marker of germinal center origin, has been associated with a favorable prognosis in diffuse large B-cell lymphoma (DLBCL). To determine the prognostic significance of this marker when rituximab (R) was added to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy, we prospectively studied Bcl-6 protein expression by immunohistochemical staining of 199 paraffin-embedded specimens from patients enrolled in the US Intergroup phase 3 trial comparing R-CHOP to CHOP with or without maintenance R. In Bcl-6– patients, failure-free survival (FFS) and overall survival (OS) were prolonged for those treated with R-CHOP alone compared to CHOP alone (2-year FFS 76% versus 9%, P < .001; 2-year OS 79% versus 17%, P < .001). In contrast, no differences in FFS and OS were detected between treatment arms for Bcl-6+ cases. In the multivariate analysis, treatment arm (CHOP versus R-CHOP) was the major determinant of both FFS (P < .001) and OS (P < .001) for the Bcl-6– subset, whereas the International Prognostic Index risk group was the only significant predictor of outcome among Bcl-6+ cases. Bcl-2 protein expression was not predictive of outcome in either group. In this study, we observed a reduction in treatment failures and death with the addition of R to CHOP in Bcl-6– DLBCL cases only. Our finding that Bcl-6+ cases did not benefit from the addition of R to CHOP requires independent confirmation. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Is it time to stop treating subsets of DLBCL with R-CHOP? Craig Moskowitz Blood 2006 107: 4197-4198. [Full Text] [PDF] This article has been cited by other articles: D. Ennishi, K. Takeuchi, M. Yokoyama, H. Asai, Y. Mishima, Y. Terui, S. Takahashi, H. Komatsu, K. Ikeda, M. Yamaguchi, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy Ann. Onc., June 23, 2008; (2008) mdn392v1. [Abstract] [Full Text] [PDF] R. Malumbres, J. Chen, R. Tibshirani, N. A. Johnson, L. H. Sehn, Y. Natkunam, J. Briones, R. Advani, J. M. Connors, G. E. Byrne, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP Blood, June 15, 2008; 111(12): 5509 - 5514. [Abstract] [Full Text] [PDF] W. H. Wilson, K. Dunleavy, S. Pittaluga, U. Hegde, N. Grant, S. M. Steinberg, M. Raffeld, M. Gutierrez, B. A. Chabner, L. Staudt, et al. Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers J. Clin. Oncol., June 1, 2008; 26(16): 2717 - 2724. [Abstract] [Full Text] [PDF] D. O. Persky, J. M. Unger, C. M. Spier, B. Stea, M. LeBlanc, M. J. McCarty, L. M. Rimsza, R. I. Fisher, and T. P. Miller Phase II Study of Rituximab Plus Three Cycles of CHOP and Involved-Field Radiotherapy for Patients With Limited-Stage Aggressive B-Cell Lymphoma: Southwest Oncology Group Study 0014 J. Clin. Oncol., May 10, 2008; 26(14): 2258 - 2263. [Abstract] [Full Text] [PDF] F. Jardin, P. Ruminy, J.-P. Kerckaert, F. Parmentier, J.-M. Picquenot, S. Quief, C. Villenet, G. Buchonnet, M. Tosi, T. Frebourg, et al. Detection of somatic quantitative genetic alterations by multiplex polymerase chain reaction for the prediction of outcome in diffuse large B-cell lymphomas Haematologica, April 1, 2008; 93(4): 543 - 550. [Abstract] [Full Text] [PDF] M. J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego, A. Younes, J. E. Romaguera, F. B. Hagemeister, L. Kwak, et al. The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma Ann. Onc., March 1, 2008; 19(3): 553 - 559. [Abstract] [Full Text] [PDF] Y. Natkunam, P. Farinha, E. D. Hsi, C. P. Hans, R. Tibshirani, L. H. Sehn, J. M. Connors, D. Gratzinger, M. Rosado, S. Zhao, et al. LMO2 Protein Expression Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy With and Without Rituximab J. Clin. Oncol., January 20, 2008; 26(3): 447 - 454. [Abstract] [Full Text] [PDF] S. Le Gouill, P. Talmant, C. Touzeau, A. Moreau, R. Garand, N. Juge-Morineau, F. Gaillard, T. Gastinne, N. Milpied, P. Moreau, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement Haematologica, October 1, 2007; 92(10): 1335 - 1342. [Abstract] [Full Text] [PDF] S. Prakash and S. H Swerdlow Nodal aggressive B-cell lymphomas: a diagnostic approach J. Clin. Pathol., October 1, 2007; 60(10): 1076 - 1085. [Abstract] [Full Text] [PDF] J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF] J. Dupuis, P. Gaulard, F. Hemery, E. Itti, C. Gisselbrecht, A. Rahmouni, C. Copie-Bergman, J. Briere, T. E. Gnaoui, I. Gaillard, et al. Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma Haematologica, June 1, 2007; 92(6): 778 - 783. [Abstract] [Full Text] [PDF] H. Nyman, M. Adde, M.-L. Karjalainen-Lindsberg, M. Taskinen, M. Berglund, R.-M. Amini, C. Blomqvist, G. Enblad, and S. Leppa Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy Blood, June 1, 2007; 109(11): 4930 - 4935. [Abstract] [Full Text] [PDF] H Veelken, S Vik Dannheim, J Schulte Moenting, U. Martens, J Finke, and A Schmitt-Graeff Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy Ann. Onc., May 1, 2007; 18(5): 931 - 939. [Abstract] [Full Text] [PDF] L. H. Sehn, B. Berry, M. Chhanabhai, C. Fitzgerald, K. Gill, P. Hoskins, R. Klasa, K. J. Savage, T. Shenkier, J. Sutherland, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP Blood, March 1, 2007; 109(5): 1857 - 1861. [Abstract] [Full Text] [PDF] K. Dunleavy, R. E. Davis, O. Landgren, L. M. Staudt, and W. H. Wilson BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we? Blood, January 15, 2007; 109(2): 843 - 844. [Full Text] [PDF] J. N. Winter, E. A. Weller, S. J. Horning, and R. D. Gascoyne Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement Blood, January 15, 2007; 109(2): 844 - 844. [Full Text] [PDF] C. H. Moskowitz, P. A. Hamlin, and A. D. Zelenetz Response: BCL6 and outcome in diffuse large B-cell lymphoma: a work in progress Blood, January 15, 2007; 109(2): 845 - 845. [Full Text] [PDF] A. Reiter Diagnosis and Treatment of Childhood Non-Hodgkin Lymphoma Hematology, January 1, 2007; 2007(1): 285 - 296. [Abstract] [Full Text] [PDF] P. Farinha, L. Sehn, B. Skinnider, J. M. Connors, and R. D. Gascoyne Addition of Rituximab (R) to CHOP Improves Survival in the Non-GCB Subtype of Diffuse Large B Cell Lymphoma (DLBCL). Blood (ASH Annual Meeting Abstracts), November 16, 2006; 108(11): 816 - 816. [Abstract] [Full Text] [PDF] L. H. Sehn Optimal Use of Prognostic Factors in Non-Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 295 - 302. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020